Literature DB >> 17998894

mTOR as a target for therapy of renal cancer.

Gary R Hudes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17998894

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  10 in total

Review 1.  Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Authors:  Pau Castel; Eneda Toska; Zachary S Zumsteg; F Javier Carmona; Moshe Elkabets; Ana Bosch; Maurizio Scaltriti
Journal:  Mol Cell Oncol       Date:  2014-10-29

2.  TPX2 in human clear cell renal carcinoma: Expression, function and prognostic significance.

Authors:  Q I Chen; Bin Cao; Ning Nan; Y U Wang; X U Zhai; Youfang Li; Tie Chong
Journal:  Oncol Lett       Date:  2016-03-31       Impact factor: 2.967

Review 3.  Dysregulation of mRNA translation and energy metabolism in cancer.

Authors:  Matthew Leibovitch; Ivan Topisirovic
Journal:  Adv Biol Regul       Date:  2017-11-02

4.  eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.

Authors:  Alpana Soni; Argun Akcakanat; Gopal Singh; David Luyimbazi; Yuhuan Zheng; Doyil Kim; Ana Gonzalez-Angulo; Funda Meric-Bernstam
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

5.  Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).

Authors:  Daniele Campa; Anika Hüsing; Angelika Stein; Lucie Dostal; Heiner Boeing; Tobias Pischon; Anne Tjønneland; Nina Roswall; Kim Overvad; Jane Nautrup Østergaard; Laudina Rodríguez; Núria Sala; Maria-José Sánchez; Nerea Larrañaga; José María Huerta; Aurelio Barricarte; Kay-Tee Khaw; Nicholas Wareham; Ruth C Travis; Naomi E Allen; Pagona Lagiou; Antonia Trichopoulou; Dimitrios Trichopoulos; Domenico Palli; Sabina Sieri; Rosario Tumino; Carlotta Sacerdote; Henk van Kranen; H Bas Bueno-de-Mesquita; Göran Hallmans; Mattias Johansson; Isabelle Romieu; Mazda Jenab; David G Cox; Afshan Siddiq; Elio Riboli; Federico Canzian; Rudolf Kaaks
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

Review 6.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

7.  Sunitinib resistance in renal cell carcinoma.

Authors:  Christudas Morais
Journal:  J Kidney Cancer VHL       Date:  2014-04-22

8.  The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray.

Authors:  Li Xiao; Yi C Wang; Wu S Li; Yan Du
Journal:  J Exp Clin Cancer Res       Date:  2009-12-13

9.  IMPA2 Downregulation Enhances mTORC1 Activity and Restrains Autophagy Initiation in Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Chia-Hao Kuei; Hui-Yu Lin; Hsun-Hua Lee; Che-Hsuan Lin; Jing-Quan Zheng; Kuan-Chou Chen; Yuan-Feng Lin
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.241

10.  Lactotransferrin Downregulation Serves as a Potential Predictor for the Therapeutic Effectiveness of mTOR Inhibitors in the Metastatic Clear Cell Renal Cell Carcinoma without PTEN Mutation.

Authors:  Jing-Quan Zheng; Che-Hsuan Lin; Hsun-Hua Lee; Wen-Ke Wang; Yiu-Shun Tong; Kang-Yun Lee; Hui-Wen Chiu; Yuan-Feng Lin
Journal:  Biomedicines       Date:  2021-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.